You may not be able to see nasal polyps, but that doesn’t mean you can’t sense their constant presence. In fact, more than ...
SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections cut total nasal polyps score by ...
Please provide your email address to receive an email when new articles are posted on . EVEREST represents the first head-to-head study of these biologics for CRSwNP. Differences between the biologics ...
THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the ...
Please provide your email address to receive an email when new articles are posted on . Nasal polyp and congestion scores dropped more with stapokibart vs. placebo. Overall nasal symptoms, sense of ...
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair ...
U.S. veterans who served in Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) face an increased risk of developing several chronic respiratory conditions, according to new research ...
"For people living with CRSwNP, every breath can feel like a struggle, and many endure years of recurring symptoms and surgeries without significant relief. The approval of TEZSPIRE represents a ...